vs
Side-by-side financial comparison of LXP Industrial Trust (LXP) and Vericel Corp (VCEL). Click either name above to swap in a different company.
Vericel Corp is the larger business by last-quarter revenue ($92.9M vs $86.7M, roughly 1.1× LXP Industrial Trust). LXP Industrial Trust runs the higher net margin — 33.2% vs 25.0%, a 8.2% gap on every dollar of revenue. On growth, Vericel Corp posted the faster year-over-year revenue change (23.3% vs -14.0%). Over the past eight quarters, Vericel Corp's revenue compounded faster (34.6% CAGR vs 0.3%).
LXP Industrial Trust is a publicly traded real estate investment trust (REIT) that owns, operates, and invests in high-quality industrial real estate assets, primarily distribution centers, logistics facilities, and light industrial properties across key markets in the United States. Its tenant base covers e-commerce, third-party logistics, and advanced manufacturing sectors, delivering stable long-term returns for its investors.
Vericel Corporation is a publicly traded American biopharmaceutical company which was known prior to October 2014 as Aastrom Bio. Aastrom Bio was formed in 1989 in Ann Arbor, Michigan.
LXP vs VCEL — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $86.7M | $92.9M |
| Net Profit | $28.8M | $23.2M |
| Gross Margin | 81.5% | 78.7% |
| Operating Margin | 34.6% | 24.1% |
| Net Margin | 33.2% | 25.0% |
| Revenue YoY | -14.0% | 23.3% |
| Net Profit YoY | — | 17.3% |
| EPS (diluted) | — | $0.46 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $86.7M | $92.9M | ||
| Q3 25 | $86.9M | $67.5M | ||
| Q2 25 | $87.7M | $63.2M | ||
| Q1 25 | $88.9M | $52.6M | ||
| Q4 24 | $100.9M | $75.4M | ||
| Q3 24 | $85.6M | $57.9M | ||
| Q2 24 | $85.8M | $52.7M | ||
| Q1 24 | $86.3M | $51.3M |
| Q4 25 | $28.8M | $23.2M | ||
| Q3 25 | $36.3M | $5.1M | ||
| Q2 25 | $29.1M | $-553.0K | ||
| Q1 25 | $19.0M | $-11.2M | ||
| Q4 24 | — | $19.8M | ||
| Q3 24 | $6.3M | $-901.0K | ||
| Q2 24 | $5.4M | $-4.7M | ||
| Q1 24 | $-269.0K | $-3.9M |
| Q4 25 | 81.5% | 78.7% | ||
| Q3 25 | 82.3% | 73.5% | ||
| Q2 25 | 81.9% | 73.7% | ||
| Q1 25 | 80.7% | 69.0% | ||
| Q4 24 | 85.3% | 77.6% | ||
| Q3 24 | 82.5% | 71.9% | ||
| Q2 24 | 82.0% | 69.5% | ||
| Q1 24 | 82.4% | 68.9% |
| Q4 25 | 34.6% | 24.1% | ||
| Q3 25 | 50.4% | 5.1% | ||
| Q2 25 | 33.7% | -3.2% | ||
| Q1 25 | 21.8% | -24.3% | ||
| Q4 24 | — | 24.5% | ||
| Q3 24 | 7.9% | -4.3% | ||
| Q2 24 | 6.9% | -11.5% | ||
| Q1 24 | 1.0% | -10.7% |
| Q4 25 | 33.2% | 25.0% | ||
| Q3 25 | 41.7% | 7.5% | ||
| Q2 25 | 33.2% | -0.9% | ||
| Q1 25 | 21.4% | -21.4% | ||
| Q4 24 | — | 26.3% | ||
| Q3 24 | 7.4% | -1.6% | ||
| Q2 24 | 6.3% | -8.9% | ||
| Q1 24 | -0.3% | -7.5% |
| Q4 25 | — | $0.46 | ||
| Q3 25 | $0.12 | $0.10 | ||
| Q2 25 | $0.09 | $-0.01 | ||
| Q1 25 | $0.06 | $-0.23 | ||
| Q4 24 | — | $0.40 | ||
| Q3 24 | $0.02 | $-0.02 | ||
| Q2 24 | $0.01 | $-0.10 | ||
| Q1 24 | $-0.01 | $-0.08 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $170.4M | $137.5M |
| Total DebtLower is stronger | $1.4B | — |
| Stockholders' EquityBook value | $2.0B | $354.6M |
| Total Assets | $3.5B | $488.0M |
| Debt / EquityLower = less leverage | 0.66× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $170.4M | $137.5M | ||
| Q3 25 | $229.7M | $135.4M | ||
| Q2 25 | $71.0M | $116.9M | ||
| Q1 25 | $70.9M | $112.9M | ||
| Q4 24 | $101.8M | $116.2M | ||
| Q3 24 | $55.0M | $101.7M | ||
| Q2 24 | $48.7M | $102.5M | ||
| Q1 24 | $293.8M | $110.6M |
| Q4 25 | $1.4B | — | ||
| Q3 25 | $1.5B | — | ||
| Q2 25 | $1.5B | — | ||
| Q1 25 | $1.5B | — | ||
| Q4 24 | $1.6B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $2.0B | $354.6M | ||
| Q3 25 | $2.1B | $321.9M | ||
| Q2 25 | $2.1B | $306.8M | ||
| Q1 25 | $2.1B | $295.5M | ||
| Q4 24 | $2.1B | $292.0M | ||
| Q3 24 | $2.1B | $257.5M | ||
| Q2 24 | $2.1B | $243.0M | ||
| Q1 24 | $2.2B | $233.9M |
| Q4 25 | $3.5B | $488.0M | ||
| Q3 25 | $3.7B | $453.3M | ||
| Q2 25 | $3.7B | $435.6M | ||
| Q1 25 | $3.8B | $424.6M | ||
| Q4 24 | $3.8B | $432.7M | ||
| Q3 24 | $3.9B | $390.4M | ||
| Q2 24 | $3.9B | $376.8M | ||
| Q1 24 | $4.2B | $356.7M |
| Q4 25 | 0.66× | — | ||
| Q3 25 | 0.72× | — | ||
| Q2 25 | 0.72× | — | ||
| Q1 25 | 0.73× | — | ||
| Q4 24 | 0.75× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $188.7M | $15.0M |
| Free Cash FlowOCF − Capex | — | $12.8M |
| FCF MarginFCF / Revenue | — | 13.8% |
| Capex IntensityCapex / Revenue | — | 2.4% |
| Cash ConversionOCF / Net Profit | 6.56× | 0.65× |
| TTM Free Cash FlowTrailing 4 quarters | — | $24.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $188.7M | $15.0M | ||
| Q3 25 | $63.5M | $22.1M | ||
| Q2 25 | $44.3M | $8.2M | ||
| Q1 25 | $39.0M | $6.6M | ||
| Q4 24 | $211.2M | $22.2M | ||
| Q3 24 | $64.6M | $10.2M | ||
| Q2 24 | $38.5M | $18.5M | ||
| Q1 24 | $38.9M | $7.2M |
| Q4 25 | — | $12.8M | ||
| Q3 25 | — | $19.5M | ||
| Q2 25 | — | $81.0K | ||
| Q1 25 | — | $-7.6M | ||
| Q4 24 | — | $8.5M | ||
| Q3 24 | — | $-9.2M | ||
| Q2 24 | — | $1.8M | ||
| Q1 24 | — | $-6.8M |
| Q4 25 | — | 13.8% | ||
| Q3 25 | — | 28.8% | ||
| Q2 25 | — | 0.1% | ||
| Q1 25 | — | -14.5% | ||
| Q4 24 | — | 11.2% | ||
| Q3 24 | — | -15.9% | ||
| Q2 24 | — | 3.4% | ||
| Q1 24 | — | -13.3% |
| Q4 25 | — | 2.4% | ||
| Q3 25 | — | 3.9% | ||
| Q2 25 | — | 12.9% | ||
| Q1 25 | — | 27.0% | ||
| Q4 24 | — | 18.3% | ||
| Q3 24 | — | 33.5% | ||
| Q2 24 | — | 31.8% | ||
| Q1 24 | — | 27.3% |
| Q4 25 | 6.56× | 0.65× | ||
| Q3 25 | 1.75× | 4.35× | ||
| Q2 25 | 1.52× | — | ||
| Q1 25 | 2.05× | — | ||
| Q4 24 | — | 1.12× | ||
| Q3 24 | 10.18× | — | ||
| Q2 24 | 7.09× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
LXP
Segment breakdown not available.
VCEL
| MACI Implants And Kits | $84.1M | 90% |
| Other | $8.8M | 10% |
